Charter Amendments, Establishments, Reestablishments, Renewals, and Terminations; Sickle Cell Advisory Committee

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published

January 23, 2026

Issuing agencies

Health and Human Services DepartmentNational Institutes of Health

Full Text

<html>
<head>
<title>Federal Register, Volume 91 Issue 15 (Friday, January 23, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 15 (Friday, January 23, 2026)]
[Notices]
[Page 2945]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-01313]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Charter Amendments, Establishments, Reestablishments, Renewals, 
and Terminations; Sickle Cell Advisory Committee

    Pursuant to Title 41 of the U.S. Code of Federal Regulations, 
Section 102-3.65(a), the Director, National Institutes of Health (NIH) 
announces the reestablishment of the Sickle Cell Disease Advisory 
Committee as authorized by 42 U.S.C. 282(b)(16), section 402(b)(16) of 
the Public Health Service Act, as amended.
    The Director, NIH, has determined that the current activities of 
the Sickle Cell Disease Advisory Committee are in the public interest 
in connection with the performance of duties imposed on NIH by law, and 
that these duties can best be performed through the advice and counsel 
of the committee.
    This committee makes recommendations on research priorities 
conducted or supported by the National Heart, Lung, and Blood Institute 
(NHLBI). The Committee also makes recommendations about long range 
plans of basic, clinical, applied, health education, and prevention 
related research concerning the scientific aspects of research programs 
on the nature, causes, diagnosis, treatment, and prevention of Sickle 
Cell Disease (SCD). By making informed recommendations on research 
priorities and long-range plans that span basic, clinical, applied, 
health education, and prevention research, the committee members play a 
pivotal role in addressing the impact of SCD on individuals.
    Inquiries may be directed to Patricia Hansberger, Acting Director, 
Office of Federal Advisory Committee Policy, Office of the Director, 
National Institutes of Health, 6701 Democracy Boulevard, Suite 1000, 
Bethesda, Maryland 20892 (Mail code 4875), Telephone (301) 594-2492, or 
<a href="/cdn-cgi/l/email-protection#eb89998a858f9f9bab848fc5858283c58c849d"><span class="__cf_email__" data-cfemail="9bf9e9faf5ffefebdbf4ffb5f5f2f3b5fcf4ed">[email&#160;protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, 
National Center for Sleep Disorders Research; 93.837, Heart and 
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, 
Blood Diseases and Resources Research, National Institutes of 
Health, HHS)

     Dated: January 16, 2026.
Jayantha Bhattacharya,
Director, National Institutes of Health.
[FR Doc. 2026-01313 Filed 1-22-26; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>

View on FederalRegister.gov →Plain-text source

Indexed from Federal Register on January 23, 2026.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.